Treatment of refractory chronic GVHD with rituximab: a GITMO study. - Wikidata - awgldk - TriplyDB

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

http://www.wikidata.org/entity/Q33375484

about

Biologics in dermatology: an integrated review Clinical utility of rituximab in chronic graft-versus-host disease.A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation Induction of B-cell immune tolerance by antigen-modified cytotoxic T lymphocytes.Pathogenesis and management of graft-versus-host disease.Allogeneic hematopoietic cell transplantation: the state of the art B cells and transplantation: an educational resource.Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.CD20, AIF-1, and TGF-beta in graft-versus-host disease: a study of mRNA expression in histologically matched skin biopsies.Biomarkers in chronic graft-versus-host disease The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study Clinical impact of H-Y alloimmunity Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease Treatment of chronic graft-versus-host disease: Past, present and future.Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation Oral graft-versus-host disease.Rippled skin, fasciitis, and joint contractures.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease Immune modulation and chronic graft-versus-host disease.Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.Novel application of lentiviral vectors towards treatment of graft-versus-host disease.Increased BCR responsiveness in B cells from patients with chronic GVHD.The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.Rituximab in hematopoietic cell transplantation.Rituximab: a review of dermatological applications.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD.B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.

P2860

Q27004638-330209D8-7401-4A95-9817-76DDA8BBD9D1 Q33383124-358C325F-3B97-46D1-A9C1-9E8877EBF113 Q33691510-F2A8DBF9-2761-439A-8F93-5073469627DB Q33749353-4C04D351-7E94-4C2E-AB89-6BB17416C0DE Q34077479-1616D3AA-5218-4B76-8D32-2DBF3038AFC1 Q34145155-CBCFAB1C-BAB7-4055-A8D1-D2F4C11DBA7A Q34152189-B20FC802-37E3-435D-A012-1FFD6EEF0FCE Q34255166-5B66A6EE-23CD-4D04-9D00-0B0A2B9347A0 Q34707354-566C2EDC-9BD3-49C8-A6A4-5022E7A3C8D3 Q34786954-20CEDA3E-AB36-4511-9E75-E9B2C879DE7D Q35094374-4441DDFF-7645-4966-9D19-13BECA14F31B Q35193763-976E3A28-3180-4BAD-846F-5027B218A3A4 Q35235186-90C587D0-B641-46C3-8DBA-4CBF230F3886 Q35300908-D9D4F118-9BB9-4EBA-AB5D-1CF3E5C00562 Q35483838-A6E9190E-AA7D-420B-8B43-B37FC25DF7F5 Q35524687-2CC4F93D-351F-4BAC-9595-74BAB01635B4 Q35930604-991A2AF9-CD06-4630-B366-A5275CACB5B7 Q35970489-FB7F2E87-ABF8-4ECB-B693-38B217B2F0E7 Q36057911-F8EB8E44-0591-49AF-BA0E-AB0205447E98 Q36250962-FCB261BB-9FA0-438A-968E-C3DCBCCE773F Q36264895-1D0CF06F-8ACA-4E41-AA7B-F23BBBA9041B Q36471247-DB87CB41-B205-468E-A66E-ABDC274FAFC8 Q36637621-8F33635F-1804-46B6-A30D-A489C0D8D652 Q36891433-58F36014-D9B8-4523-BBD6-66E7FC04F7DF Q36932886-B3234FC7-96D5-40E4-AE8F-B1F9D87F589B Q36991852-29B2489A-35B9-467F-BEE8-5D2CD7215C88 Q37113099-DB22D639-77CB-40C8-9996-18F0B1378AF1 Q37162874-5D72AED1-678B-4A8A-BDEF-CA9B4F416079 Q37251057-FA4F8B50-2D80-4B3B-B9E0-FBDA3010F43E Q37468247-468501AA-BA96-4B69-9E4A-EC847D9C7B59 Q37489887-D722978C-1FFA-4AB1-A023-EFBB2DEF8621 Q37670076-5E91B0B2-93AB-4933-88B7-7AAB402BFD0B Q37689179-7B58C44D-4E4C-4CF6-BB35-4148F2239EE7 Q37737311-181B28C4-7AE7-45CD-BB5C-17D94775E3EA Q37781697-7A4F4758-920E-424F-A5E3-A7475579740B Q37810286-0C75FE82-6FDF-4599-A206-3451BCDBE2AC Q37843939-4BDD398B-C86D-4BA1-ABDF-8D80F2B9F4BD Q37851519-0E9C8810-7277-488C-972B-61B4F1E35337 Q37861866-40AC89B9-4EB5-4AA5-A098-C73B2C201139 Q37899200-00DADED2-6182-43B9-B4A6-2D2834316CF2

P2860

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

http://www.wikidata.org/entity/Q33375484

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@ast

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@en

type

label

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@ast

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@en

prefLabel

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@ast

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

@en

P1433

Q33375484-D9D4D0B4-173E-4AD5-935E-776E3061A812

P1476

Q33375484-A0A8C3FC-D00F-4206-A20D-33AC36014B96

P2093

Q33375484-0563F0A7-B24F-401A-92C1-59E3AA4C8228

Q33375484-068E70AE-8372-404B-AF4E-7D4E16D2D19E

Q33375484-10FDCA3F-A793-4FD2-929D-E37F950E14A2

Q33375484-15198294-08FE-4666-B9C7-943B14EF433D

Q33375484-1FFC31DE-102A-4E56-9C70-7CB634E264D3

Q33375484-287A5B48-4630-4522-9F90-3B3314D8A2DE

Q33375484-3C6AF478-5012-4937-BBBD-EEA08EFD40A8

Q33375484-7CA63B81-BC8A-4DE5-84AD-ED02DF4FC284

Q33375484-7DF2EFD1-25E1-4714-A0D2-2174B8474518

Q33375484-8B57D906-A9A9-4E26-A43B-3FE5246A668E

P2888

Q33375484-B730A8DF-03D3-4C14-9ED9-C32D0F839FDA

P304

Q33375484-A32AF35E-8E26-4102-ABC7-8063703A6CBB

P31

Q33375484-5841DC07-7EE4-4CB1-9722-B8596E590EF3

P356

Q33375484-5DD9D425-1B6C-4CE7-8536-69834EDBAA33

P407

Q33375484-D472F2C9-745E-42C4-AD31-5BF7E2B3B218

P433

Q33375484-84ED83B5-F310-49B7-ADB1-79ED37FF7681

P478

Q33375484-67064B8C-97B2-42DD-96BF-D84EAA25BFD3

P50

Q33375484-49438C81-A0BA-400B-A5D8-13A0A52CD544

Q33375484-4EE6A258-89C7-4624-B085-7116952DAF24

Q33375484-50D74853-1C1F-43A8-A4AF-12EA128FAB04

Q33375484-5F3A19CC-54A5-4774-94BC-8EC506721ECA

Q33375484-C29F972A-9E6F-4D9C-A2ED-D5629EF29FCE

Q33375484-EBF0D35C-75DE-4438-81DD-A9F9ED25B42C

P577

Q33375484-5A7C8A03-330D-450B-9E82-E39D38441423

P5875

Q33375484-105E940A-9F3D-4B71-BEFE-61589092A30A

P6179

Q33375484-78908598-9ACF-4342-8618-16362256892A

P698

Q33375484-815793D3-2507-4659-9FFD-431A3C78CFD9

P356

P1433

Bone Marrow Transplantation

P1476

Treatment of refractory chronic GVHD with rituximab: a GITMO study

@en

P2093

A Bacigalupo

http://www.w3.org/2001/XMLSchema#string

A Olivieri

http://www.w3.org/2001/XMLSchema#string

A Sperotto

http://www.w3.org/2001/XMLSchema#string

C Filì

http://www.w3.org/2001/XMLSchema#string

C Vener

http://www.w3.org/2001/XMLSchema#string

D Laszlo

http://www.w3.org/2001/XMLSchema#string

F Patriarca

http://www.w3.org/2001/XMLSchema#string

GITMO (Gruppo Italiano Trapianto Midollo Osseo)

http://www.w3.org/2001/XMLSchema#string

M Falda

http://www.w3.org/2001/XMLSchema#string

M T Van Lint

http://www.w3.org/2001/XMLSchema#string

P2888

P304

273-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705725

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Bonifazi

Giuseppe Milone

P577

2007-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6287690

http://www.w3.org/2001/XMLSchema#string

P6179

1015224245

http://www.w3.org/2001/XMLSchema#string

P698

17549053

http://www.w3.org/2001/XMLSchema#string